Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

Pharmaceutical company Eli Lilly has submitted an application for U.S. approval of its weight loss drug, Zepbound, to treat obstructive sleep apnea (OSA). The company anticipates a decision by the end of the year. Recent data from two late-stage trials showed that Zepbound effectively resolved OSA symptoms in nearly half of the patients. The results provide further evidence of the potential health benefits associated with weight loss and diabetes treatments. If approved, Eli Lilly plans to launch Zepbound in early 2025.